There are 2 articles on this stock available only to PRO subscribers.
- AmpliPhi reported Q3 earnings last week.
- I reiterate my bull thesis.
- As expected, AmpliPhi continues to advance its core phage programs to human clinical trials in 2015. The Q3 earnings report corroborates this position.
- AmpliPhi announces the resignation of CEO Philip Young.
- I reiterate my bull thesis as the company remains on track to advance AMP-002 to Phase 1 clinical trials early next year.
- I didn't anticipate the departure of Mr. Young. Nevertheless, it appears that it is a nonevent for shareholders.
AmpliPhi Biosciences: Developer Of Antibacterial 'Smartbombs'
- AmpliPhi Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of bacteriophage treatments for bacterial infections.
- The company has three lead compounds in development ready to enter clinical trials in the next 6-12 months.
- We believe AmpliPhi has an exciting technology and is a company investors should put on their watch list.
AmpliPhi Biosciences: A Speculative Play In Biopharmaceuticals Too Compelling To Ignore
- AmpliPhi is a virtually unknown small-cap biopharmaceutical company listed on the OTC.
- Its bacteriophage therapies could have a profound impact on the anti-infective sector, but more importantly, patients suffering from a variety of antibiotic-resistant infections.
- The significant share ownership of Randall J. Kirk, a tycoon of the biopharmaceutical industry, is a testament to the company's potential to reshape the treatment modality for infectious diseases.
- We believe the company is a compelling speculative play as its long-term drug prospects look promising, and management is exhausting all avenues to ensure the success of their clinical programs.
There are no Transcripts on APHB.
Fri, Sep. 19, 8:10 AM
Thu, Aug. 21, 4:04 PM
- Ampliphi Biosciences (OTCQB:APHB +11.4%) restates its financial statements for the quarters ended September 30, 2013, December 31, 2013 and March 31, 2014 and for the year ended December 31, 3013 due to non-cash adjustments related to its Series B Preferred Stock dividend clause to reflect its treatment as a compound derivative.
- It will restate its financials for the year ended December 31, 2013 due to a reclassification of in-process R&D related to its acquisition of Biocontrol Ltd.
- The financials for the years ended December 31, 2011, 2012 and 2013 will be revised to recognize amortization of certain patents.
Fri, Apr. 4, 4:41 PM
- Ampliphi Biosciences (APHB -5.2%) reports that its financial statements for the period ending September 30,2013 can no longer be relied upon.
- The Company's treatment of the non-cash impact of its Series B Preferred Stock, certain promissory notes and certain warrants issued in June and July 2013 should have accounted for them as derivative instruments because they contain anti-dilution protections. Post-issue value fluctuations should then be recorded as non-cash income or expense.
- The firm's 2013 10-K will include a discussion of material weaknesses in its internal controls over financial reporting.
APHB vs. ETF Alternatives
Other News & PR